TY - JOUR
T1 - The ADEM2 project
T2 - early pathogenic mechanisms of preschool wheeze and a randomised controlled trial assessing the gain in health and cost-effectiveness by application of the breath test for the diagnosis of asthma in wheezing preschool children
AU - ADEM2 Consortium
AU - Kienhorst, Sophie
AU - van Aarle, Moniek H.D.
AU - Jöbsis, Quirijn
AU - Bannier, Michiel A.G.E.
AU - Kersten, Elin T.G.
AU - Damoiseaux, Jan
AU - van Schayck, Onno C.P.
AU - Merkus, Peter J.F.M.
AU - Koppelman, Gerard H.
AU - van Schooten, Frederik Jan
AU - van der Sande, Linda J.T.M.
AU - van Horck, Marieke
AU - Smolinska, Agnieszka
AU - Dompeling, Edward
N1 - Funding Information:
The ADEM2 study is supported by The Netherlands Organisation for Health Research (ZonMW) (project number 848101008), a Netherlands Lung Foundation Grant (project number 6.1.18.221), and two grants of Top Sector Life Sciences and Health Health (TKI Topconsortia voor Kennis en Innovatie) (project number 10.1.17.183 and LSHM17071). These funding bodies assessed the design of the study in their grant application processes, but have no role in collection, analysis or interpretation of data. Genomic analysis in the ADEM2 is supported by a ZON-MW VICI grant to Gerard Koppelman (project number 09150182110046). Eosinophil analysis is funded by a grant from the Beatrix Children’s Hospital Foundation.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023
Y1 - 2023
N2 - Background: The prevalence of asthma-like symptoms in preschool children is high. Despite numerous efforts, there still is no clinically available diagnostic tool to discriminate asthmatic children from children with transient wheeze at preschool age. This leads to potential overtreatment of children outgrowing their symptoms, and to potential undertreatment of children who turn out to have asthma. Our research group developed a breath test (using GC-tof–MS for VOC-analysis in exhaled breath) that is able to predict a diagnosis of asthma at preschool age. The ADEM2 study assesses the improvement in health gain and costs of care with the application of this breath test in wheezing preschool children. Methods: This study is a combination of a multi-centre, parallel group, two arm, randomised controlled trial and a multi-centre longitudinal observational cohort study. The preschool children randomised into the treatment arm of the RCT receive a probability diagnosis (and corresponding treatment recommendations) of either asthma or transient wheeze based on the exhaled breath test. Children in the usual care arm do not receive a probability diagnosis. Participants are longitudinally followed up until the age of 6 years. The primary outcome is disease control after 1 and 2 years of follow-up. Participants of the RCT, together with a group of healthy preschool children, also contribute to the parallel observational cohort study developed to assess the validity of alternative VOC-sensing techniques and to explore numerous other potential discriminating biological parameters (such as allergic sensitisation, immunological markers, epigenetics, transcriptomics, microbiomics) and the subsequent identification of underlying disease pathways and relation to the discriminative VOCs in exhaled breath. Discussion: The potential societal and clinical impact of the diagnostic tool for wheezing preschool children is substantial. By means of the breath test, it will become possible to deliver customized and high qualitative care to the large group of vulnerable preschool children with asthma-like symptoms. By applying a multi-omics approach to an extensive set of biological parameters we aim to explore (new) pathogenic mechanisms in the early development of asthma, creating potentially interesting targets for the development of new therapies. Trial registration: Netherlands Trial Register, NL7336, Date registered 11–10-2018.
AB - Background: The prevalence of asthma-like symptoms in preschool children is high. Despite numerous efforts, there still is no clinically available diagnostic tool to discriminate asthmatic children from children with transient wheeze at preschool age. This leads to potential overtreatment of children outgrowing their symptoms, and to potential undertreatment of children who turn out to have asthma. Our research group developed a breath test (using GC-tof–MS for VOC-analysis in exhaled breath) that is able to predict a diagnosis of asthma at preschool age. The ADEM2 study assesses the improvement in health gain and costs of care with the application of this breath test in wheezing preschool children. Methods: This study is a combination of a multi-centre, parallel group, two arm, randomised controlled trial and a multi-centre longitudinal observational cohort study. The preschool children randomised into the treatment arm of the RCT receive a probability diagnosis (and corresponding treatment recommendations) of either asthma or transient wheeze based on the exhaled breath test. Children in the usual care arm do not receive a probability diagnosis. Participants are longitudinally followed up until the age of 6 years. The primary outcome is disease control after 1 and 2 years of follow-up. Participants of the RCT, together with a group of healthy preschool children, also contribute to the parallel observational cohort study developed to assess the validity of alternative VOC-sensing techniques and to explore numerous other potential discriminating biological parameters (such as allergic sensitisation, immunological markers, epigenetics, transcriptomics, microbiomics) and the subsequent identification of underlying disease pathways and relation to the discriminative VOCs in exhaled breath. Discussion: The potential societal and clinical impact of the diagnostic tool for wheezing preschool children is substantial. By means of the breath test, it will become possible to deliver customized and high qualitative care to the large group of vulnerable preschool children with asthma-like symptoms. By applying a multi-omics approach to an extensive set of biological parameters we aim to explore (new) pathogenic mechanisms in the early development of asthma, creating potentially interesting targets for the development of new therapies. Trial registration: Netherlands Trial Register, NL7336, Date registered 11–10-2018.
KW - Asthma
KW - Biomarkers
KW - Breath test
KW - Diagnosis
KW - Exhaled VOC
KW - Pathogenesis
KW - Preschool
KW - Wheeze
U2 - 10.1186/s12889-023-15465-6
DO - 10.1186/s12889-023-15465-6
M3 - Article
C2 - 37013496
AN - SCOPUS:85151656941
SN - 1471-2458
VL - 23
JO - BMC Public Health
JF - BMC Public Health
IS - 1
M1 - 629
ER -